Application progress of single-cell RNA sequencing technology in breast development and related diseases.
10.11817/j.issn.1672-7347.2025.250039
- Author:
Shiyi WEN
1
;
Yang HU
2
;
Xiangyu CHEN
2
;
Jianda ZHOU
2
;
Ping LI
3
Author Information
1. Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China. 576015848@qq.com.
2. Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
3. Department of Burn and Plastic Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China. 993850347@qq.com.
- Publication Type:English Abstract
- Keywords:
breast cancer;
breast development;
embryonic multipotent progenitors;
macromastia;
single-cell RNA sequencing;
transcriptomics
- MeSH:
Humans;
Single-Cell Analysis/methods*;
Female;
Breast Neoplasms/pathology*;
Sequence Analysis, RNA/methods*;
Breast/cytology*
- From:
Journal of Central South University(Medical Sciences)
2025;50(6):1080-1087
- CountryChina
- Language:Chinese
-
Abstract:
The spatio-temporal heterogeneity of breast cell subsets forms the fundamental biological basis for physiological development and pathological progression, including tumorigenesis; however, its complex regulatory mechanisms are not yet fully elucidated. With its high-resolution capabilities, single-cell RNA sequencing (scRNA-seq) technology offers a powerful tool for dissecting this cellular heterogeneity. This technology enables the construction of high-precision breast cell atlases, the accurate identification of distinct cell subsets, and the reconstruction of differentiation trajectories from stem/progenitor cells to functional epithelial cells. By resolving the transcriptional regulatory networks that govern cell fate determination, intercellular communication patterns, and dynamic microenvironmental interactions, scRNA-seq has unveiled the molecular foundations of breast development and provided new perspectives on the pathogenesis of related diseases such as breast cancer and macromastia. Furthermore, scRNA-seq demonstrates significant potential for discovering early molecular markers of disease, deciphering tumor heterogeneity, and elucidating mechanisms of therapeutic resistance. The continued application of scRNA-seq for dissecting breast cell heterogeneity, combined with its integration with multi-modal data such as spatial omics, promises to provide critical evidence and new insights for revealing the molecular mechanisms of breast development-related diseases and for formulating precision therapeutic strategies.
